Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease

Completed · Phase 1

Conditions studied: Lesch-Nyhan Disease

In brief

The purpose of this study is to determine the effects of ecopipam in patients with Lesch-Nyhan Disease (LND). Ecopipam specifically blocks the actions of one chemical in the brain that helps nerves talk to one another; ecopipam does this by stopping the chemical (dopamine) from binding to one of its family of receptors (i.e, the D1 family). LND is a very rare genetic disease. The sponsor is doing this study to find out what side effects ecopipam causes in LND patients, and whether ecopipam may be able to relieve the self-injurious behaviors seen in these patients.

Key facts

Study ID

NCT01065558

Run by

Psyadon Pharma

People needed

5

Starts

2010-02-01

Expected to finish

2011-06-01

Last updated by the study team

2013-04-18

Who can join

Age: 6 and older, up to 65. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Lesch-Nyhan disease with moderate to severe Self- Injurious Behavior and are routinely restrained
• Male - 6 years of age and above
• Body weight greater than or equal to 44 pounds

You may not qualify if…

• Taking Neuroleptic or Dopamine Depleting medications
• Currently treated with medications for depression or seizures
• Impaired renal function
• Medical conditions that may interfere with completing the study

Where it is running

• University of California at San Diego — San Diego, California, United States
• Emory Univesity — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.